| Cash Flow | 2025-09-30 |
|---|---|
| Effect of exchange rate changes on cash | 29 |
| Net loss | -8,423 |
| Depreciation | 23 |
| Share-based compensation | 2,040 |
| The amount of finance income (expenses), net | 8 |
| Increase in other current assets | 219 |
| Decrease (increase) in accounts receivable | -126 |
| Increase (decrease) in accounts payable | 84 |
| Increase (decrease) in accrued liabilities and other operating liabilities | 840 |
| Net cash provided by (used in) operating activities | -5,537 |
| Purchase of property and equipment | 80 |
| Net cash provided by (used in) investing activities | -80 |
| Proceeds from issuance of common stock | 6,254 |
| The amount represents proceeds from issuance of shares under collaboration agreement | 7,190 |
| Issuance cost | 262 |
| Proceeds from warrant exercises | 354 |
| Net cash provided by (used in) financing activities | 13,536 |
| Cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), excluding exchange rate effect, including discontinued operation | 7,919 |
| Cash and cash equivalents at beginning of period | 8,740 |
| Cash and cash equivalents at end of period | 16,688 |
Entera Bio Ltd. (ENTX)
Entera Bio Ltd. (ENTX)